Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in epithelioid sarcoma

Jia Xiang Jin; Fabia Fuchslocher; Martha Carreno-Gonzalez; Felina Zahnow; A. Katharina Ceranski; Rainer Will; Dominic Helm; Felix Bestvater; Ana Banito; Roland Imle; Shunya Ohmura; Florencia Cidre-Aranaz; Thomas G. P. Grünewald

doi:10.1002/cac2.12665

Cancer Communications ›› 2025, Vol. 45 ›› Issue (5) : 494 -499. DOI: 10.1002/cac2.12665

LETTER TO THE JOURNAL

Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in epithelioid sarcoma

Jia Xiang Jin ¹^,²^,³^,⁴
, Fabia Fuchslocher ¹^,²^,³^,⁴
, Martha Carreno-Gonzalez ¹^,²^,³^,⁴
, Felina Zahnow ¹^,²^,⁴
, A. Katharina Ceranski ¹^,²^,³^,⁴
, Rainer Will ⁵
, Dominic Helm ⁶
, Felix Bestvater ⁷
, Ana Banito ¹^,⁴^,⁸
, Roland Imle ¹^,⁴^,⁸^,⁹^,¹⁰
, Shunya Ohmura ¹^,²^,⁴
, Florencia Cidre-Aranaz ¹^,²^,⁴
, Thomas G. P. Grünewald ¹^,²^,⁴^,¹¹

Author information +

¹. Hopp-Children's Cancer Center (KiTZ), Heidelberg, Baden-Württemberg, Germany

². Division of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Baden-Württemberg, Germany

³. Medical Faculty, Ruprecht-Karls-University, Heidelberg, Baden-Württemberg, Germany

⁴. National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Baden-Württemberg, Germany

⁵. Core Facility Cellular Tools (W111), German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Baden-Württemberg, Germany

⁶. Core Facility Proteomics (W120), German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Baden-Württemberg, Germany

⁷. Light Microscopy Core Facility (W210), German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Baden-Württemberg, Germany

⁸. Soft-Tissue Sarcoma Junior Research Group, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Baden-Württemberg, Germany

⁹. Faculty of Biosciences, Heidelberg University, Heidelberg, Baden-Württemberg, Germany

¹⁰. Division of Pediatric Surgery, Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany

¹¹. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Baden-Württemberg, Germany

t.gruenewald@dkfz-heidelberg.de

Show less

History +

PDF

Cite this article

Download citation ▾

Jia Xiang Jin, Fabia Fuchslocher, Martha Carreno-Gonzalez, Felina Zahnow, A. Katharina Ceranski, Rainer Will, Dominic Helm, Felix Bestvater, Ana Banito, Roland Imle, Shunya Ohmura, Florencia Cidre-Aranaz, Thomas G. P. Grünewald. Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in epithelioid sarcoma. Cancer Communications, 2025, 45(5): 494-499 DOI:10.1002/cac2.12665

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Enzinger FM. Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970; 26(5): 1029-41.

[2]	Grünewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, et al. Translational Aspects of Epithelioid Sarcoma: Current Consensus. Clin Cancer Res. 2024; 30(6): 1079-92.

[3]	Moe KC, Maxwell JN, Wang J, Jones CA, Csaki GT, Florian AC, et al. The SWI/SNF ATPase BRG1 facilitates multiple pro-tumorigenic gene expression programs in SMARCB1-deficient cancer cells. Oncogenesis. 2022; 11(1): 30.

[4]	Wolf BK, Zhao Y, McCray A, Hawk WH, Deary LT, Sugiarto NW, et al. Cooperation of chromatin remodeling SWI/SNF complex and pioneer factor AP-1 shapes 3D enhancer landscapes. Nat Struct Mol Biol. 2023; 30(1): 10-21.

[5]	Radko-Juettner S, Yue H, Myers JA, Carter RD, Robertson AN, Mittal P, et al. Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF. Nature. 2024; 628(8007): 442-9.

[6]	Zhu Z, Chen X, Guo A, Manzano T, Walsh PJ, Wills KM, et al. Mitotic bookmarking by SWI/SNF subunits. Nature. 2023; 618(7963): 180-187.

[7]	Nakayama RT, Pulice JL, Valencia AM, McBride MJ, McKenzie ZM, Gillespie MA, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017; 49(11): 1613-23.

[8]	Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022; 601(7893): 434-9.

[9]	Papillon JPN, Nakajima K, Adair CD, Hempel J, Jouk AO, Karki RG, et al. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers. Journal of medicinal chemistry. 2018; 61(22): 10155-72.

[10]	Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo HS, et al. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angew Chem Int Ed Engl. 2017; 56(21): 5738-43.

[11]	Mo Y, Duan S, Zhang X, Hua X, Zhou H, Wei HJ, et al. Epigenome programing by H3.3K27M mutation creates a dependence of pediatric glioma on SMARCA4. Cancer Discov. 2022; 12(12): 2906-29.